September 26, 2025 • 18 mins
Could your “normal” cholesterol panel be hiding dangerous particles that drive heart disease? In this episode of The Health Pulse, we reveal why standard lipid testing often misses the real culprits behind plaque formation: small dense LDL particles (sdLDL).
We explore the four key reasons sdLDL is so harmful—its ability to penetrate arterial walls, its high susceptibility to oxidation, its extended circulation time, and its potent inflammatory effects. Most importantly, we connect sdLDL directly to insulin resistance and metabolic dysfunction, showing how diet, visceral fat, and sedentary lifestyles create this dangerous lipid pattern.
You’ll also learn about the advanced tests that provide a clearer risk picture—LDL particle number (LDL-P) and Apolipoprotein B (ApoB)—and why these markers can reveal hidden cardiovascular risk even when your cholesterol looks “normal.”
If you’ve been told your cholesterol is fine but still worry about heart disease, this episode offers critical insights that could change how you think about prevention.
📞 Need lab work done from the comfort of home? QLM offers fast, reliable mobile phlebotomy services—no clinic visit required.
📅 Book your appointment or learn more at:
👉 Quick Lab Mobile
📧 Contact us: info@quicklabmobile.com
💬 Enjoyed the episode? Leave us a review and let us know what topics you'd like us to cover next! Your feedback helps us bring you the content that matters most.
Disclaimer: The information provided in this podcast is for informational purposes only and should not be considered medical advice. The content discussed is based on research, expert insights, and reputable sources, but it does not replace professional medical consultation, diagnosis, or treatment. We strive to present accurate and up-to-date information, medical research is constantly evolving. Listeners should always verify details with trusted health organizations, before making any health-related decisions. If you are experiencing a medical emergency, such as severe pain, difficulty breathing, or other urgent symptoms, call your local emergency services immediately. By listening to this podcast, you acknowledge that The Health Pulse and its creators are not responsible for any actions taken based on the content of this episode. Your health and well-being should always be guided by the advice of qualified medical professionals.
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
SPEAKER_00 (00:00):
Welcome to the Health Pulse, your go-to source
for quick, actionable insightson health, wellness, and
diagnostics.
Whether you're looking tooptimize your well-being or stay
informed about the latestin-medical testing, we've got
you covered.
Join us as we break down keyhealth topics in just minutes.
Let's dive in.
SPEAKER_01 (00:25):
Welcome back to the deep dive.
We are uh ripping the cover offa central mystery in cardiology
today.
Why do some people developsevere heart disease and even
suffer heart attacks despitehaving cholesterol reports that
their doctor calls normal?
SPEAKER_02 (00:41):
It's a huge question.
And one that causes a lot ofconfusion.
SPEAKER_01 (00:44):
Yeah, the standard lipid panel, you know, the one
everyone gets, it seems to havethis massive blind spot.
SPEAKER_02 (00:50):
It really does.
SPEAKER_01 (00:51):
And if you have underlying metabolic issues,
that blind spot could be hiding,well, a ticking cardiovascular
clock.
SPEAKER_02 (00:58):
That's precisely it.
SPEAKER_01 (00:59):
So today we're diving into the central idea
that proves, maybe once and forall, that not all LDL
cholesterol is created equal.
SPEAKER_02 (01:07):
Aaron Powell That's absolutely right.
Our mission today really is tomove the conversation past just
looking at LDLC.
SPEAKER_01 (01:14):
That single number.
SPEAKER_02 (01:15):
Yeah, that single number which measures the total
mass of cholesterol beingtransported.
We need to zero in on the actualparticles.
SPEAKER_01 (01:21):
Okay.
SPEAKER_02 (01:21):
Specifically their size, their number, and their
density.
These are the delivery vehicleswe need to understand.
SPEAKER_01 (01:27):
And introduce the main player.
SPEAKER_02 (01:28):
Exactly.
We need to introduce you to themost potent, arguably the most
dangerous subtype, small denseLDL or SDLDL.
SPEAKER_01 (01:37):
Okay, let's unpack this because this really does
change the game, doesn't it?
SPEAKER_02 (01:41):
Completely.
SPEAKER_01 (01:41):
For decades, the mantra has basically been if
your LDLC is low, you're safe.
But what you're saying is LDLConly measures the cargo, the
amount of cholesterol.
SPEAKER_02 (01:51):
Just the amount.
SPEAKER_01 (01:52):
It tells us nothing about the trucks carrying it.
Are they big, easy to manage,18-wheelers, or or like a swarm
of thousands of tiny, aggressivedrones?
SPEAKER_02 (02:01):
Trevor Burrus, Jr.: That analogy perfectly captures
the distinction.
It's so critical because twopeople can walk out of a lab
with the exact same LDLC number,say 100.
SPEAKER_01 (02:10):
And they're told their risk is identical.
SPEAKER_02 (02:11):
Aaron Powell Exactly.
They walk away thinking they'rein the same boat.
SPEAKER_01 (02:14):
Aaron Powell But the reality could be night and day
different.
SPEAKER_02 (02:16):
Aaron Powell Precisely.
Individual A might have maybe athousand large, harmless,
buoyant particles carrying that100 milligrams of cholesterol.
These are pretty easy for thebody to handle.
Okay.
But individual B, well, theymight need 2,500 of those tiny
dense particles to carry theexact same 100 milligrams of
cholesterol mass.
SPEAKER_01 (02:35):
Wow, more than double the particles.
SPEAKER_02 (02:37):
Aaron Powell Right.
And it's the particle number,not just the cholesterol mass
inside them that truly drivesthe risk.
SPEAKER_01 (02:42):
Aaron Powell Because the standard LDLC testing misses
particle number and sizecompletely.
SPEAKER_02 (02:46):
Aaron Powell It does.
So two people with the same LDLCscore can have, I mean, just
drastically different levels ofcardiovascular risk.
Trevor Burrus, Jr.
SPEAKER_01 (02:54):
So let's focus on the real culprit then, SDLDL.
You said they're characterizedby their small size and high
density.
Why is that small size such aliability when it comes to, you
know, arterial damage?
SPEAKER_02 (03:06):
Aaron Powell Well, the key features of SDLDL are
exactly what make themfundamentally more anthrogenic.
That just means more likely tocause plaque in the arteries.
More dangerous.
Yes.
First, their smaller diameter iscritical.
Think of the inner lining ofyour arteries, the endothelium,
like a protective barrier,almost like a sieve.
SPEAKER_01 (03:23):
Okay.
SPEAKER_02 (03:24):
The large fluffy LDL particles.
They're generally too big tosqueeze through easily.
SPEAKER_01 (03:28):
They sort of bounce off.
SPEAKER_02 (03:29):
Exactly.
But the small diameter of SDLDLallows them to penetrate that
arterial wall much more easily.
They slip into what's called thesub-endothelial space.
SPEAKER_01 (03:40):
Aaron Powell So they get trapped behind the barrier.
SPEAKER_02 (03:42):
They get trapped, accumulate, and start building
up the foundation for plaque.
That's step one.
SPEAKER_01 (03:47):
Aaron Powell And the second characteristic you
mentioned, higher density, meansthey're carrying less actual
cholesterol per particle, right?
SPEAKER_02 (03:53):
Yes, that's right.
They're denser because they'rerelatively depleted of
triglycerides and cholesterolesters compared to the larger
ones.
They're like tiny hard packages.
SPEAKER_01 (04:03):
Though you need more of them.
SPEAKER_02 (04:04):
You need many more of them.
To move the same amount ofcholesterol, your body has to
produce and release a muchgreater number of these small
dense particles.
SPEAKER_01 (04:14):
And that explains why APOB testing is so
important.
SPEAKER_02 (04:17):
Precisely.
APOLIPO protein B, or APOB,measures the total count of
these potentially plaque-causingparticles.
It's a far, far superior riskpredictor than LDLC.
SPEAKER_01 (04:27):
Aaron Powell Because more particles means more
traffic trying to get throughthat barrier.
SPEAKER_02 (04:32):
Exactly.
More chances for things to gowrong.
SPEAKER_01 (04:34):
Aaron Powell Okay, here's where it gets really
interesting.
Once these tiny particlesactually penetrate the artery
wall, what happens next?
Let's get into the specificmechanisms you mentioned for
that turn this particle sizeinto hard, dangerous plaque.
SPEAKER_02 (04:49):
Aaron Powell Right.
So that initial step, theenhanced arterial penetration,
that just sets the stage.
Once they're trapped in thatintimal space, they're exposed
to a pretty hostile environment.
SPEAKER_01 (04:58):
Aaron Powell And I understand step two involves
oxidation.
SDLDL seems, I don't know,structurally prone to damage.
SPEAKER_02 (05:04):
Aaron Powell It is.
It's far more susceptible tomodification.
Inside the artery wall, theseSDLDL particles are easily
attacked by free radicals.
They undergo oxidativemodification.
SPEAKER_01 (05:14):
Aaron Powell And when SDLDL gets oxidized, it
produces OxLDL.
SPEAKER_02 (05:19):
Oxidized LDL or OXLDL, yes.
And this stuff is highlyinflammatory.
It's really a destructive formof cholesterol that the immune
system sees as basically aninvading enemy.
SPEAKER_01 (05:28):
So the immune system kicks in, tries to clean up this
perceived threat.
SPEAKER_02 (05:32):
Aaron Powell Right.
And that aggressive immuneresponse is actually what
creates the plaque itself.
Immune cells called macrophages.
They're like the cleanup crew.
They engulf the Ox LDL, but theycan't really process it
effectively.
They just get stuffed full andturn into what we call foam
cells.
SPEAKER_00 (05:46):
Foam cells, okay.
SPEAKER_02 (05:47):
And these foam cells aggregate, they clump together,
forming the fatty streaks youhear about, and eventually the
fibrous plaques thatcharacterize heart disease.
SPEAKER_01 (05:56):
Okay, so penetration, then oxidation
leading to foam cells.
What's the third mechanism?
It's about exposure time.
If these particles are so bad,the longer they're around, the
worse it is.
SPEAKER_02 (06:06):
Absolutely.
The third key mechanism is theirlonger circulation time.
They just stick around longer.
SPEAKER_01 (06:11):
Why is that?
SPEAKER_02 (06:12):
The metabolic machinery in the liver, which is
supposed to clear out old ordamaged LDL from the blood, it's
just less efficient atrecognizing and removing these
SDLDL particles.
They do.
They persist longer in thebloodstream compared to their
larger cousins.
This increases the totalexposure time for your artery
walls.
SPEAKER_01 (06:30):
Aaron Powell Which means more opportunities to slip
in and get oxidized.
SPEAKER_02 (06:34):
Exactly.
Many more opportunities forvessel penetration and that
dangerous oxidation process.
SPEAKER_01 (06:39):
Okay, so they slip in easily, get damaged almost
immediately, and they stay incirculation longer.
Sounds like a perfect storm forchronic inflammation.
SPEAKER_02 (06:47):
Aaron Powell And that leads directly into the
fourth mechanism, thepro-inflammatory effects and the
structural damage they cause.
Right.
Once oxidized, SDLDL is apowerful trigger.
It ramps up immune cellactivation, contributes to
endothelial dysfunction, meaningthe artery lining stops working
properly.
SPEAKER_01 (07:05):
Aaron Powell Which makes things even worse.
SPEAKER_02 (07:06):
Aaron Powell It does.
And importantly, it promotes theproliferation, the growth of
smooth muscle cells within theartery wall.
This stiffens the artery,thickens it, and ultimately
makes the plaque unstable andmore prone to rupture.
SPEAKER_01 (07:20):
Aaron Powell, which is, of course, what causes heart
attacks and strokes.
SPEAKER_02 (07:23):
That's the critical event, yes.
SPEAKER_01 (07:24):
Aaron Powell So taken together, these four
properties easy penetration,easy oxidation, long
circulation, and inflammation,explain why just focusing on
LDLC is, well, potentiallydangerous.
SPEAKER_02 (07:35):
It can be dangerously misleading.
SPEAKER_01 (07:37):
SDLDL seems perfectly designed to start and
progress the blockage process,even if your total cholesterol
mass looks fine on paper.
SPEAKER_02 (07:44):
This naturally raises an important question.
If SDLDL is this primary hiddenrisk factor and the total
cholesterol number can bemisleading, what actually causes
the elevation of these specifictiny particles?
SPEAKER_01 (07:59):
Yeah, because it sounds like we aren't just
talking about, you know, eatingtoo much dietary fat anymore.
SPEAKER_02 (08:03):
We're certainly not.
The data, it's prettyunequivocal now.
Elevated SDLDL isn't just anisolated plumbing problem in
your arteries.
SPEAKER_01 (08:11):
It's a symptom.
SPEAKER_02 (08:11):
It's a profound reflection of underlying
metabolic failure.
The core cause, in most cases,is insulin resistance and the
cluster of issues known asmetabolic syndrome.
SPEAKER_01 (08:22):
Okay, that link seems fundamental.
SPEAKER_02 (08:24):
It is.
When your body becomes insulinresistant, its ability to manage
blood sugar is compromised.
This metabolic statedramatically alters lipid
metabolism, how your bodyhandles fats.
SPEAKER_00 (08:34):
How so?
SPEAKER_02 (08:35):
Specifically, insulin resistance leads to an
increased production oftriglyceride-rich lipoproteins,
VLDLs mostly.
SPEAKER_01 (08:41):
Which are basically fat carriers, right?
SPEAKER_02 (08:43):
Exactly.
And when these triglyceride-richparticles interact with the
larger, buoyant LDL particles inyour blood, an enzyme called
CETP cholesterol ester transferprotein gets hyperactive.
SPEAKER_01 (08:56):
What does CETP do?
SPEAKER_02 (08:57):
It essentially swaps components between particles.
It strips cholesterol esters outof the normal LDL and replaces
them with triglycerides from theV LDL.
SPEAKER_01 (09:06):
So the LDL gets loaded up with triglycerides.
SPEAKER_02 (09:09):
Right.
This creates a newtriglyceride-rich LDL particle.
Then other enzymes process thisfurther, stripping away those
newly acquired triglycerides andwhat's left behind.
SPEAKER_01 (09:18):
The small, dense LDL.
SPEAKER_02 (09:20):
The small, dense, highly dangerous STLDL.
It's literally a conversionprocess, driven entirely by your
underlying metabolic state,particularly how you handle
carbs and sugar.
SPEAKER_01 (09:29):
So high levels of SDLDL are really a symptom of
the insulin resistance, not theprimary illness itself.
And this is heavily influencedby diet you mentioned.
SPEAKER_02 (09:37):
Oh, absolutely.
The sources strongly connecthigh carbohydrate and especially
high sugar diets to this wholeproblem.
These diets are known todramatically increase
triglycerides.
That's the fuel for theconversion process we just
discussed.
And they also tend to lower HDLcholesterol, the good
cholesterol.
Both factors strongly favor theshift toward SDLDL dominance.
SPEAKER_01 (09:57):
So it's a cascading metabolic failure, often driven
by too much glucose andfructose.
SPEAKER_02 (10:02):
Largely, yes.
From processed foods, sugarydrinks, excessive carbs relative
to your metabolic tolerance.
SPEAKER_01 (10:10):
And beyond diet, there are physical factors, like
obesity, specifically belly fat.
SPEAKER_02 (10:15):
Yes.
Excess abdominal or visceralfat, the fat stored around your
organs, is strongly associatedwith SDLDL dominance.
SPEAKER_01 (10:21):
Why that fat in particular?
SPEAKER_02 (10:23):
Aaron Ross Powell Because visceral fat is highly
metabolically active.
It churns out inflammatorysignals and hormones that fuel
chronic inflammation and worsenthat whole cycle of insulin
resistance.
SPEAKER_01 (10:32):
Makes sense.
And lifestyle activity levels.
SPEAKER_02 (10:34):
Of course.
Low physical activity just makesall these factors worse.
It promotes insulin resistance,raises triglycerides, and
basically maximizes the SDLDLconversion rate.
SPEAKER_01 (10:43):
So lifestyle is the major lever here.
SPEAKER_02 (10:46):
It really is.
Though we should mentiongenetics can play a role too.
Certain genetic variations, likeApoE polymorphisms, can make
some individuals a bit morepredisposed to this SDLDL
pattern, even with good habits.
But for most, it's lifestyledriven.
SPEAKER_01 (11:03):
This shift in focus feels critical.
We're moving from, you know,just blaming butter to really
examining sugar metabolism andsedentary habits.
SPEAKER_02 (11:12):
Aaron Powell That's a good way to put it.
SPEAKER_01 (11:13):
And the evidence confirming that SDLDL is a
better predictor of heart riskis substantial, right?
That's what justifies this deepdive.
SPEAKER_02 (11:21):
Aaron Powell Oh, it's beyond debate now in the
research community.
Major prospective studies likethe Quebec cardiovascular study
and the very long-runningFramingham offspring study, they
confirmed this pattern decadesago.
SPEAKER_01 (11:32):
What did they find, essentially?
SPEAKER_02 (11:33):
They demonstrated conclusively that individuals
with a higher proportion ofSDLDL had a significantly
increased risk of coronaryartery disease.
Period.
SPEAKER_01 (11:42):
And the really key finding was that this elevated
risk remained true even after.
SPEAKER_02 (11:47):
Even after they statistically adjusted for total
LDLC and even triglyceridelevels.
That's crucial.
It confirms SDLDL is anindependent risk factor for
coronary heart disease.
SPEAKER_01 (11:58):
Meaning it adds risk information above and beyond the
standard numbers.
SPEAKER_02 (12:02):
Correct.
And this risk is especiallypronounced in patients already
dealing with type 2 diabetes ormetabolic syndrome.
If you have those conditions,SDLDL is very likely driving
your cardiovascular risk.
SPEAKER_01 (12:14):
And we can actually see the physical evidence now,
can't we?
The data connects SDLDL directlyto actual plaque formation
measured with modern imaging.
SPEAKER_02 (12:23):
Exactly.
Clinical imaging reallyreinforces this.
Studies using coronary arterycalcium scoring, the CAC score,
or carotid intima mediathickness, CIMT, they show a
much stronger correlationbetween higher SDLDL levels and
subclinical atherosclerosis.
SPEAKER_01 (12:37):
Which is the actual physical buildup of plaque
before symptoms start.
SPEAKER_02 (12:40):
Right.
A much stronger correlation thanstandard lipid measures like
LDLC show.
Basically, the particle sizepredicts the plaque burden
better.
SPEAKER_01 (12:47):
Okay, this makes it clear.
If a patient has any signs ofmetabolic syndrome, high blood
sugar, belly fat, hightriglycerides, low HDL, and they
only rely on a standardcholesterol panel, they are
potentially missing crucialdata.
SPEAKER_02 (13:00):
They absolutely are.
SPEAKER_01 (13:01):
So since SDLDL is this hidden variable in standard
testing, what specialized labtests are crucial for someone to
get a complete cardiovascularrisk picture, especially those
folks with metabolic issues.
SPEAKER_02 (13:13):
We absolutely need to pivot.
We need to move from measuringcholesterol mass to measuring
particle count and size.
Advanced lipid testing isnecessary here.
SPEAKER_01 (13:21):
Aaron Powell Like what specifically?
SPEAKER_02 (13:23):
Look for tests that explicitly provide LDL particle
number, usually written as LDLP.
That number is often the singlemost important predictor of
risk.
SPEAKER_01 (13:31):
More important than LDLC.
SPEAKER_02 (13:32):
Often, yes, especially when LDLC and LDLP
tell different stories, whichhappens frequently in insulin
resistance.
These advanced panels, like NMRlapoprofile or cardio IQ, will
also specify the percentage orquantity of SDLDL, letting you
know if you have that dangerouspattern of predominantly small
particles.
SPEAKER_01 (13:51):
Okay, LDLP and SDLDL quantification.
What about other markers thattie back to the particle count?
You mentioned APO B earlier.
SPEAKER_02 (13:59):
APOLIPOProtein B or APOB is non-negotiable in my
view.
Remember, there's one APOBmolecule on every single
atherogenic particle, LDL, VLDLremnants, IDL.
SPEAKER_01 (14:11):
So it's a direct count of all the bad guys.
SPEAKER_02 (14:14):
It's essentially a direct count of all potentially
plaque forming particles,including SDLDL.
If your APOB is high, you have ahigh number of these particles
and thus a higher risk, almostregardless of what your LDLC
value says.
SPEAKER_01 (14:27):
If you only remember one number today, maybe make it
APOB.
SPEAKER_02 (14:31):
It's certainly a top contender for the single best
marker.
SPEAKER_01 (14:34):
And since we've established this entire problem
is so deeply rooted in metabolichealth, we have to look at the
context of glucose and insulintoo, surely.
SPEAKER_02 (14:41):
Absolutely.
Advanced lipid panels are kindof incomplete without also
measuring markers ofinflammation like high
sensitivity, CRP, HSERP, andcrucially your glucose and
insulin status.
SPEAKER_01 (14:51):
What tests there?
SPEAKER_02 (14:52):
Fasting glucose, HBA1C, which shows your average
blood sugar over months, andideally fasting insulin levels.
These tell us the severity ofyour underlying insulin
resistance.
SPEAKER_01 (15:02):
And that gives you the reason why the SDLDL is
high.
SPEAKER_02 (15:05):
Exactly.
It provides the why.
You can't effectively treat theSDLDL particle pattern long term
without addressing the rootcause, the metabolic
dysfunction, the insulinresistance.
SPEAKER_01 (15:16):
And the good news maybe is that getting this kind
of deep insight is becomingeasier.
The sources mentioned the growthof services offering these
advanced lipid panels andmetabolic testing.
SPEAKER_02 (15:25):
Yes.
Accessibility is improving.
SPEAKER_01 (15:27):
Options like at-home specimen collection, I think
Quick Lab Mobile was mentionedfor Miami, make proactive
monitoring more convenient forpeople who really want to take
control.
SPEAKER_02 (15:38):
That convenience factor is transformative, I
think.
Getting this detailed dataallows doctors and patients to
personalize lifestyle changesand, if necessary, treatments
that target the cause of theinsulin resistance.
Trevor Burrus, Jr.
SPEAKER_01 (15:49):
Which then naturally reduces the SDLDL particle
count.
SPEAKER_02 (15:52):
Right.
It's a much more targeted andeffective approach than just
blindly prescribing a statinsometimes to chase a standard
LDL C number that might not evenbe the main problem for that
individual.
It doesn't tell the whole story.
SPEAKER_01 (16:03):
Aaron Powell So what does this all mean then?
Let's try to wrap this up.
The key takeaway seems simple,but profound.
Small dense LDL is a powerful,often hidden driver of
atherosclerosis.
It's really not just about theamount of cholesterol you carry,
but the nature, the type of theparticles carrying it.
SPEAKER_02 (16:23):
Aaron Powell Precisely.
Size and number matterimmensely.
SPEAKER_01 (16:26):
And if you have normal cholesterol on a standard
test, but you also haveunderlying issues like insulin
resistance, maybe some extrabelly fat, prediabetes, or
full-blown diabetes.
SPEAKER_02 (16:35):
Then SDLDL could absolutely be the reason your
actual cardiovascular risk isdangerously elevated, despite
that normal report.
SPEAKER_01 (16:42):
Identifying this specific particle pattern
through tests like LDLP or APOBcan literally be the difference
between getting a falselyreassuring result and uncovering
an urgent but thankfullytreatable risk factor.
SPEAKER_02 (16:54):
That's well said.
And maybe that leads us to afinal provocative thought for
you, the listener, to consider.
Okay.
Given that SDLDL elevation is sodeeply and intrinsically tied to
insulin resistance, metabolicsyndrome, and diets high in
refined carbohydrates and sugar.
SPEAKER_01 (17:08):
The things that fuel that conversion process we
talked about.
SPEAKER_02 (17:11):
Exactly.
Given that link, the traditionaldecades-long focus almost
exclusively on dietary fat asthe main villain for heart
health well may needsignificant, perhaps permanent
reevaluation.
The true heart risk for manypeople might be less about the
fat they eat and much, much moreabout how their body processes
sugars and carbs, because that'swhat ultimately dictates the
(17:33):
size, density, and number oftheir dangerous LDL particles.
SPEAKER_00 (17:37):
Food for thought.com.
(17:58):
Stay informed, stay healthy, andwe'll catch you in the next
episode.
Welcome to the Health Pulse, your go-to source
for quick, actionable insightson health, wellness, and
diagnostics.
Whether you're looking tooptimize your well-being or stay
informed about the latestin-medical testing, we've got
you covered.
Join us as we break down keyhealth topics in just minutes.
Let's dive in.
SPEAKER_01 (00:25):
Welcome back to the deep dive.
We are uh ripping the cover offa central mystery in cardiology
today.
Why do some people developsevere heart disease and even
suffer heart attacks despitehaving cholesterol reports that
their doctor calls normal?
SPEAKER_02 (00:41):
It's a huge question.
And one that causes a lot ofconfusion.
SPEAKER_01 (00:44):
Yeah, the standard lipid panel, you know, the one
everyone gets, it seems to havethis massive blind spot.
SPEAKER_02 (00:50):
It really does.
SPEAKER_01 (00:51):
And if you have underlying metabolic issues,
that blind spot could be hiding,well, a ticking cardiovascular
clock.
SPEAKER_02 (00:58):
That's precisely it.
SPEAKER_01 (00:59):
So today we're diving into the central idea
that proves, maybe once and forall, that not all LDL
cholesterol is created equal.
SPEAKER_02 (01:07):
Aaron Powell That's absolutely right.
Our mission today really is tomove the conversation past just
looking at LDLC.
SPEAKER_01 (01:14):
That single number.
SPEAKER_02 (01:15):
Yeah, that single number which measures the total
mass of cholesterol beingtransported.
We need to zero in on the actualparticles.
SPEAKER_01 (01:21):
Okay.
SPEAKER_02 (01:21):
Specifically their size, their number, and their
density.
These are the delivery vehicleswe need to understand.
SPEAKER_01 (01:27):
And introduce the main player.
SPEAKER_02 (01:28):
Exactly.
We need to introduce you to themost potent, arguably the most
dangerous subtype, small denseLDL or SDLDL.
SPEAKER_01 (01:37):
Okay, let's unpack this because this really does
change the game, doesn't it?
SPEAKER_02 (01:41):
Completely.
SPEAKER_01 (01:41):
For decades, the mantra has basically been if
your LDLC is low, you're safe.
But what you're saying is LDLConly measures the cargo, the
amount of cholesterol.
SPEAKER_02 (01:51):
Just the amount.
SPEAKER_01 (01:52):
It tells us nothing about the trucks carrying it.
Are they big, easy to manage,18-wheelers, or or like a swarm
of thousands of tiny, aggressivedrones?
SPEAKER_02 (02:01):
Trevor Burrus, Jr.: That analogy perfectly captures
the distinction.
It's so critical because twopeople can walk out of a lab
with the exact same LDLC number,say 100.
SPEAKER_01 (02:10):
And they're told their risk is identical.
SPEAKER_02 (02:11):
Aaron Powell Exactly.
They walk away thinking they'rein the same boat.
SPEAKER_01 (02:14):
Aaron Powell But the reality could be night and day
different.
SPEAKER_02 (02:16):
Aaron Powell Precisely.
Individual A might have maybe athousand large, harmless,
buoyant particles carrying that100 milligrams of cholesterol.
These are pretty easy for thebody to handle.
Okay.
But individual B, well, theymight need 2,500 of those tiny
dense particles to carry theexact same 100 milligrams of
cholesterol mass.
SPEAKER_01 (02:35):
Wow, more than double the particles.
SPEAKER_02 (02:37):
Aaron Powell Right.
And it's the particle number,not just the cholesterol mass
inside them that truly drivesthe risk.
SPEAKER_01 (02:42):
Aaron Powell Because the standard LDLC testing misses
particle number and sizecompletely.
SPEAKER_02 (02:46):
Aaron Powell It does.
So two people with the same LDLCscore can have, I mean, just
drastically different levels ofcardiovascular risk.
Trevor Burrus, Jr.
SPEAKER_01 (02:54):
So let's focus on the real culprit then, SDLDL.
You said they're characterizedby their small size and high
density.
Why is that small size such aliability when it comes to, you
know, arterial damage?
SPEAKER_02 (03:06):
Aaron Powell Well, the key features of SDLDL are
exactly what make themfundamentally more anthrogenic.
That just means more likely tocause plaque in the arteries.
More dangerous.
Yes.
First, their smaller diameter iscritical.
Think of the inner lining ofyour arteries, the endothelium,
like a protective barrier,almost like a sieve.
SPEAKER_01 (03:23):
Okay.
SPEAKER_02 (03:24):
The large fluffy LDL particles.
They're generally too big tosqueeze through easily.
SPEAKER_01 (03:28):
They sort of bounce off.
SPEAKER_02 (03:29):
Exactly.
But the small diameter of SDLDLallows them to penetrate that
arterial wall much more easily.
They slip into what's called thesub-endothelial space.
SPEAKER_01 (03:40):
Aaron Powell So they get trapped behind the barrier.
SPEAKER_02 (03:42):
They get trapped, accumulate, and start building
up the foundation for plaque.
That's step one.
SPEAKER_01 (03:47):
Aaron Powell And the second characteristic you
mentioned, higher density, meansthey're carrying less actual
cholesterol per particle, right?
SPEAKER_02 (03:53):
Yes, that's right.
They're denser because they'rerelatively depleted of
triglycerides and cholesterolesters compared to the larger
ones.
They're like tiny hard packages.
SPEAKER_01 (04:03):
Though you need more of them.
SPEAKER_02 (04:04):
You need many more of them.
To move the same amount ofcholesterol, your body has to
produce and release a muchgreater number of these small
dense particles.
SPEAKER_01 (04:14):
And that explains why APOB testing is so
important.
SPEAKER_02 (04:17):
Precisely.
APOLIPO protein B, or APOB,measures the total count of
these potentially plaque-causingparticles.
It's a far, far superior riskpredictor than LDLC.
SPEAKER_01 (04:27):
Aaron Powell Because more particles means more
traffic trying to get throughthat barrier.
SPEAKER_02 (04:32):
Exactly.
More chances for things to gowrong.
SPEAKER_01 (04:34):
Aaron Powell Okay, here's where it gets really
interesting.
Once these tiny particlesactually penetrate the artery
wall, what happens next?
Let's get into the specificmechanisms you mentioned for
that turn this particle sizeinto hard, dangerous plaque.
SPEAKER_02 (04:49):
Aaron Powell Right.
So that initial step, theenhanced arterial penetration,
that just sets the stage.
Once they're trapped in thatintimal space, they're exposed
to a pretty hostile environment.
SPEAKER_01 (04:58):
Aaron Powell And I understand step two involves
oxidation.
SDLDL seems, I don't know,structurally prone to damage.
SPEAKER_02 (05:04):
Aaron Powell It is.
It's far more susceptible tomodification.
Inside the artery wall, theseSDLDL particles are easily
attacked by free radicals.
They undergo oxidativemodification.
SPEAKER_01 (05:14):
Aaron Powell And when SDLDL gets oxidized, it
produces OxLDL.
SPEAKER_02 (05:19):
Oxidized LDL or OXLDL, yes.
And this stuff is highlyinflammatory.
It's really a destructive formof cholesterol that the immune
system sees as basically aninvading enemy.
SPEAKER_01 (05:28):
So the immune system kicks in, tries to clean up this
perceived threat.
SPEAKER_02 (05:32):
Aaron Powell Right.
And that aggressive immuneresponse is actually what
creates the plaque itself.
Immune cells called macrophages.
They're like the cleanup crew.
They engulf the Ox LDL, but theycan't really process it
effectively.
They just get stuffed full andturn into what we call foam
cells.
SPEAKER_00 (05:46):
Foam cells, okay.
SPEAKER_02 (05:47):
And these foam cells aggregate, they clump together,
forming the fatty streaks youhear about, and eventually the
fibrous plaques thatcharacterize heart disease.
SPEAKER_01 (05:56):
Okay, so penetration, then oxidation
leading to foam cells.
What's the third mechanism?
It's about exposure time.
If these particles are so bad,the longer they're around, the
worse it is.
SPEAKER_02 (06:06):
Absolutely.
The third key mechanism is theirlonger circulation time.
They just stick around longer.
SPEAKER_01 (06:11):
Why is that?
SPEAKER_02 (06:12):
The metabolic machinery in the liver, which is
supposed to clear out old ordamaged LDL from the blood, it's
just less efficient atrecognizing and removing these
SDLDL particles.
They do.
They persist longer in thebloodstream compared to their
larger cousins.
This increases the totalexposure time for your artery
walls.
SPEAKER_01 (06:30):
Aaron Powell Which means more opportunities to slip
in and get oxidized.
SPEAKER_02 (06:34):
Exactly.
Many more opportunities forvessel penetration and that
dangerous oxidation process.
SPEAKER_01 (06:39):
Okay, so they slip in easily, get damaged almost
immediately, and they stay incirculation longer.
Sounds like a perfect storm forchronic inflammation.
SPEAKER_02 (06:47):
Aaron Powell And that leads directly into the
fourth mechanism, thepro-inflammatory effects and the
structural damage they cause.
Right.
Once oxidized, SDLDL is apowerful trigger.
It ramps up immune cellactivation, contributes to
endothelial dysfunction, meaningthe artery lining stops working
properly.
SPEAKER_01 (07:05):
Aaron Powell Which makes things even worse.
SPEAKER_02 (07:06):
Aaron Powell It does.
And importantly, it promotes theproliferation, the growth of
smooth muscle cells within theartery wall.
This stiffens the artery,thickens it, and ultimately
makes the plaque unstable andmore prone to rupture.
SPEAKER_01 (07:20):
Aaron Powell, which is, of course, what causes heart
attacks and strokes.
SPEAKER_02 (07:23):
That's the critical event, yes.
SPEAKER_01 (07:24):
Aaron Powell So taken together, these four
properties easy penetration,easy oxidation, long
circulation, and inflammation,explain why just focusing on
LDLC is, well, potentiallydangerous.
SPEAKER_02 (07:35):
It can be dangerously misleading.
SPEAKER_01 (07:37):
SDLDL seems perfectly designed to start and
progress the blockage process,even if your total cholesterol
mass looks fine on paper.
SPEAKER_02 (07:44):
This naturally raises an important question.
If SDLDL is this primary hiddenrisk factor and the total
cholesterol number can bemisleading, what actually causes
the elevation of these specifictiny particles?
SPEAKER_01 (07:59):
Yeah, because it sounds like we aren't just
talking about, you know, eatingtoo much dietary fat anymore.
SPEAKER_02 (08:03):
We're certainly not.
The data, it's prettyunequivocal now.
Elevated SDLDL isn't just anisolated plumbing problem in
your arteries.
SPEAKER_01 (08:11):
It's a symptom.
SPEAKER_02 (08:11):
It's a profound reflection of underlying
metabolic failure.
The core cause, in most cases,is insulin resistance and the
cluster of issues known asmetabolic syndrome.
SPEAKER_01 (08:22):
Okay, that link seems fundamental.
SPEAKER_02 (08:24):
It is.
When your body becomes insulinresistant, its ability to manage
blood sugar is compromised.
This metabolic statedramatically alters lipid
metabolism, how your bodyhandles fats.
SPEAKER_00 (08:34):
How so?
SPEAKER_02 (08:35):
Specifically, insulin resistance leads to an
increased production oftriglyceride-rich lipoproteins,
VLDLs mostly.
SPEAKER_01 (08:41):
Which are basically fat carriers, right?
SPEAKER_02 (08:43):
Exactly.
And when these triglyceride-richparticles interact with the
larger, buoyant LDL particles inyour blood, an enzyme called
CETP cholesterol ester transferprotein gets hyperactive.
SPEAKER_01 (08:56):
What does CETP do?
SPEAKER_02 (08:57):
It essentially swaps components between particles.
It strips cholesterol esters outof the normal LDL and replaces
them with triglycerides from theV LDL.
SPEAKER_01 (09:06):
So the LDL gets loaded up with triglycerides.
SPEAKER_02 (09:09):
Right.
This creates a newtriglyceride-rich LDL particle.
Then other enzymes process thisfurther, stripping away those
newly acquired triglycerides andwhat's left behind.
SPEAKER_01 (09:18):
The small, dense LDL.
SPEAKER_02 (09:20):
The small, dense, highly dangerous STLDL.
It's literally a conversionprocess, driven entirely by your
underlying metabolic state,particularly how you handle
carbs and sugar.
SPEAKER_01 (09:29):
So high levels of SDLDL are really a symptom of
the insulin resistance, not theprimary illness itself.
And this is heavily influencedby diet you mentioned.
SPEAKER_02 (09:37):
Oh, absolutely.
The sources strongly connecthigh carbohydrate and especially
high sugar diets to this wholeproblem.
These diets are known todramatically increase
triglycerides.
That's the fuel for theconversion process we just
discussed.
And they also tend to lower HDLcholesterol, the good
cholesterol.
Both factors strongly favor theshift toward SDLDL dominance.
SPEAKER_01 (09:57):
So it's a cascading metabolic failure, often driven
by too much glucose andfructose.
SPEAKER_02 (10:02):
Largely, yes.
From processed foods, sugarydrinks, excessive carbs relative
to your metabolic tolerance.
SPEAKER_01 (10:10):
And beyond diet, there are physical factors, like
obesity, specifically belly fat.
SPEAKER_02 (10:15):
Yes.
Excess abdominal or visceralfat, the fat stored around your
organs, is strongly associatedwith SDLDL dominance.
SPEAKER_01 (10:21):
Why that fat in particular?
SPEAKER_02 (10:23):
Aaron Ross Powell Because visceral fat is highly
metabolically active.
It churns out inflammatorysignals and hormones that fuel
chronic inflammation and worsenthat whole cycle of insulin
resistance.
SPEAKER_01 (10:32):
Makes sense.
And lifestyle activity levels.
SPEAKER_02 (10:34):
Of course.
Low physical activity just makesall these factors worse.
It promotes insulin resistance,raises triglycerides, and
basically maximizes the SDLDLconversion rate.
SPEAKER_01 (10:43):
So lifestyle is the major lever here.
SPEAKER_02 (10:46):
It really is.
Though we should mentiongenetics can play a role too.
Certain genetic variations, likeApoE polymorphisms, can make
some individuals a bit morepredisposed to this SDLDL
pattern, even with good habits.
But for most, it's lifestyledriven.
SPEAKER_01 (11:03):
This shift in focus feels critical.
We're moving from, you know,just blaming butter to really
examining sugar metabolism andsedentary habits.
SPEAKER_02 (11:12):
Aaron Powell That's a good way to put it.
SPEAKER_01 (11:13):
And the evidence confirming that SDLDL is a
better predictor of heart riskis substantial, right?
That's what justifies this deepdive.
SPEAKER_02 (11:21):
Aaron Powell Oh, it's beyond debate now in the
research community.
Major prospective studies likethe Quebec cardiovascular study
and the very long-runningFramingham offspring study, they
confirmed this pattern decadesago.
SPEAKER_01 (11:32):
What did they find, essentially?
SPEAKER_02 (11:33):
They demonstrated conclusively that individuals
with a higher proportion ofSDLDL had a significantly
increased risk of coronaryartery disease.
Period.
SPEAKER_01 (11:42):
And the really key finding was that this elevated
risk remained true even after.
SPEAKER_02 (11:47):
Even after they statistically adjusted for total
LDLC and even triglyceridelevels.
That's crucial.
It confirms SDLDL is anindependent risk factor for
coronary heart disease.
SPEAKER_01 (11:58):
Meaning it adds risk information above and beyond the
standard numbers.
SPEAKER_02 (12:02):
Correct.
And this risk is especiallypronounced in patients already
dealing with type 2 diabetes ormetabolic syndrome.
If you have those conditions,SDLDL is very likely driving
your cardiovascular risk.
SPEAKER_01 (12:14):
And we can actually see the physical evidence now,
can't we?
The data connects SDLDL directlyto actual plaque formation
measured with modern imaging.
SPEAKER_02 (12:23):
Exactly.
Clinical imaging reallyreinforces this.
Studies using coronary arterycalcium scoring, the CAC score,
or carotid intima mediathickness, CIMT, they show a
much stronger correlationbetween higher SDLDL levels and
subclinical atherosclerosis.
SPEAKER_01 (12:37):
Which is the actual physical buildup of plaque
before symptoms start.
SPEAKER_02 (12:40):
Right.
A much stronger correlation thanstandard lipid measures like
LDLC show.
Basically, the particle sizepredicts the plaque burden
better.
SPEAKER_01 (12:47):
Okay, this makes it clear.
If a patient has any signs ofmetabolic syndrome, high blood
sugar, belly fat, hightriglycerides, low HDL, and they
only rely on a standardcholesterol panel, they are
potentially missing crucialdata.
SPEAKER_02 (13:00):
They absolutely are.
SPEAKER_01 (13:01):
So since SDLDL is this hidden variable in standard
testing, what specialized labtests are crucial for someone to
get a complete cardiovascularrisk picture, especially those
folks with metabolic issues.
SPEAKER_02 (13:13):
We absolutely need to pivot.
We need to move from measuringcholesterol mass to measuring
particle count and size.
Advanced lipid testing isnecessary here.
SPEAKER_01 (13:21):
Aaron Powell Like what specifically?
SPEAKER_02 (13:23):
Look for tests that explicitly provide LDL particle
number, usually written as LDLP.
That number is often the singlemost important predictor of
risk.
SPEAKER_01 (13:31):
More important than LDLC.
SPEAKER_02 (13:32):
Often, yes, especially when LDLC and LDLP
tell different stories, whichhappens frequently in insulin
resistance.
These advanced panels, like NMRlapoprofile or cardio IQ, will
also specify the percentage orquantity of SDLDL, letting you
know if you have that dangerouspattern of predominantly small
particles.
SPEAKER_01 (13:51):
Okay, LDLP and SDLDL quantification.
What about other markers thattie back to the particle count?
You mentioned APO B earlier.
SPEAKER_02 (13:59):
APOLIPOProtein B or APOB is non-negotiable in my
view.
Remember, there's one APOBmolecule on every single
atherogenic particle, LDL, VLDLremnants, IDL.
SPEAKER_01 (14:11):
So it's a direct count of all the bad guys.
SPEAKER_02 (14:14):
It's essentially a direct count of all potentially
plaque forming particles,including SDLDL.
If your APOB is high, you have ahigh number of these particles
and thus a higher risk, almostregardless of what your LDLC
value says.
SPEAKER_01 (14:27):
If you only remember one number today, maybe make it
APOB.
SPEAKER_02 (14:31):
It's certainly a top contender for the single best
marker.
SPEAKER_01 (14:34):
And since we've established this entire problem
is so deeply rooted in metabolichealth, we have to look at the
context of glucose and insulintoo, surely.
SPEAKER_02 (14:41):
Absolutely.
Advanced lipid panels are kindof incomplete without also
measuring markers ofinflammation like high
sensitivity, CRP, HSERP, andcrucially your glucose and
insulin status.
SPEAKER_01 (14:51):
What tests there?
SPEAKER_02 (14:52):
Fasting glucose, HBA1C, which shows your average
blood sugar over months, andideally fasting insulin levels.
These tell us the severity ofyour underlying insulin
resistance.
SPEAKER_01 (15:02):
And that gives you the reason why the SDLDL is
high.
SPEAKER_02 (15:05):
Exactly.
It provides the why.
You can't effectively treat theSDLDL particle pattern long term
without addressing the rootcause, the metabolic
dysfunction, the insulinresistance.
SPEAKER_01 (15:16):
And the good news maybe is that getting this kind
of deep insight is becomingeasier.
The sources mentioned the growthof services offering these
advanced lipid panels andmetabolic testing.
SPEAKER_02 (15:25):
Yes.
Accessibility is improving.
SPEAKER_01 (15:27):
Options like at-home specimen collection, I think
Quick Lab Mobile was mentionedfor Miami, make proactive
monitoring more convenient forpeople who really want to take
control.
SPEAKER_02 (15:38):
That convenience factor is transformative, I
think.
Getting this detailed dataallows doctors and patients to
personalize lifestyle changesand, if necessary, treatments
that target the cause of theinsulin resistance.
Trevor Burrus, Jr.
SPEAKER_01 (15:49):
Which then naturally reduces the SDLDL particle
count.
SPEAKER_02 (15:52):
Right.
It's a much more targeted andeffective approach than just
blindly prescribing a statinsometimes to chase a standard
LDL C number that might not evenbe the main problem for that
individual.
It doesn't tell the whole story.
SPEAKER_01 (16:03):
Aaron Powell So what does this all mean then?
Let's try to wrap this up.
The key takeaway seems simple,but profound.
Small dense LDL is a powerful,often hidden driver of
atherosclerosis.
It's really not just about theamount of cholesterol you carry,
but the nature, the type of theparticles carrying it.
SPEAKER_02 (16:23):
Aaron Powell Precisely.
Size and number matterimmensely.
SPEAKER_01 (16:26):
And if you have normal cholesterol on a standard
test, but you also haveunderlying issues like insulin
resistance, maybe some extrabelly fat, prediabetes, or
full-blown diabetes.
SPEAKER_02 (16:35):
Then SDLDL could absolutely be the reason your
actual cardiovascular risk isdangerously elevated, despite
that normal report.
SPEAKER_01 (16:42):
Identifying this specific particle pattern
through tests like LDLP or APOBcan literally be the difference
between getting a falselyreassuring result and uncovering
an urgent but thankfullytreatable risk factor.
SPEAKER_02 (16:54):
That's well said.
And maybe that leads us to afinal provocative thought for
you, the listener, to consider.
Okay.
Given that SDLDL elevation is sodeeply and intrinsically tied to
insulin resistance, metabolicsyndrome, and diets high in
refined carbohydrates and sugar.
SPEAKER_01 (17:08):
The things that fuel that conversion process we
talked about.
SPEAKER_02 (17:11):
Exactly.
Given that link, the traditionaldecades-long focus almost
exclusively on dietary fat asthe main villain for heart
health well may needsignificant, perhaps permanent
reevaluation.
The true heart risk for manypeople might be less about the
fat they eat and much, much moreabout how their body processes
sugars and carbs, because that'swhat ultimately dictates the
(17:33):
size, density, and number oftheir dangerous LDL particles.
SPEAKER_00 (17:37):
Food for thought.com.
(17:58):
Stay informed, stay healthy, andwe'll catch you in the next
episode.
Popular Podcasts
On Purpose with Jay Shetty
I’m Jay Shetty host of On Purpose the worlds #1 Mental Health podcast and I’m so grateful you found us. I started this podcast 5 years ago to invite you into conversations and workshops that are designed to help make you happier, healthier and more healed. I believe that when you (yes you) feel seen, heard and understood you’re able to deal with relationship struggles, work challenges and life’s ups and downs with more ease and grace. I interview experts, celebrities, thought leaders and athletes so that we can grow our mindset, build better habits and uncover a side of them we’ve never seen before. New episodes every Monday and Friday. Your support means the world to me and I don’t take it for granted — click the follow button and leave a review to help us spread the love with On Purpose. I can’t wait for you to listen to your first or 500th episode!
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
The Joe Rogan Experience
The official podcast of comedian Joe Rogan.